dr. B (Brenda) Leeneman

Erasmus School of Health Policy & Management

Assistant professor | Health Technology Assessment (HTA)

Email: leeneman@eshpm.eur.nl

Pure profile

Work

Saskia de Groot, Hedwig M. Blommestein, Brenda Leeneman, Carin A. Uyl-de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk & Pieter H.M. van Baal (2025) - Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma - Medical Decision Making, 45 (3), 302-317 - doi: 10.1177/0272989X251319338 - [link]
Hedwig M. Blommestein, Saskia de Groot, Brenda Leeneman, Carin A. Uyl-de Groot, John B.A.G. Haanen, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Willeke A.M. Blokx, Marye J. Boers-Sonderen, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Olivier J. van Not, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk & Margreet G. Franken (2025) - Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model - European Journal of Cancer, 218 - doi: 10.1016/j.ejca.2024.115071 - [link]
N. S.H. Xander, B. Leeneman, A. M.C. Dingemans, W. E. Fiets, W. K. de Jong, N. E.M. Uyl, A. N.M. Wymenga, A. K.L. Reyners & C. A. Uyl-de Groot (2024) - Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: Viable or not? - European Journal of Cancer, 209 - doi: 10.1016/j.ejca.2024.114262 - [link]
Olivier J. van Not, Alfons J.M. van den Eertwegh, Hilde Jalving, Manja Bloem, John B. Haanen, Rozemarijn S. van Rijn, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan Willem de Groot J W B, Geke A.P. Hospers, Ellen Kapiteijn, Brenda Leeneman, Piersma D, Marion Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil G, Michel W.J.M. Wouters, Willeke A.M. Blokx & Karijn P.M. Suijkerbuijk (2024) - Long-Term Survival in Patients With Advanced Melanoma - JAMA network open, 7 (8) - doi: 10.1001/jamanetworkopen.2024.26641 - [link]
Brenda Leeneman, Nicolas S.H. Xander, W. Edward Fiets, Wouter K. de Jong, Nathalie E.M. Uyl, A. N.Machteld Wymenga, An K.L. Reyners & Carin A. Uyl-de Groot (2024) - Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness - European Journal of Cancer, 202 - doi: 10.1016/j.ejca.2024.114002 - [link]
Brenda Leeneman, Hedwig M. Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E. Fibbe, Liesbeth Oosten, Carin A. Uyl-de Groot & Frederick W. Thielen (2023) - Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease - European Journal of Haematology, 111 (2), 240-246 - doi: 10.1111/ejh.13987 - [link]
M. G. Franken, B. Leeneman, M. J.B. Aarts, A. C.J. van Akkooi, F. W.P.J. van den Berkmortel, M. J. Boers-Sonderen, A. J.M. van den Eertwegh, J. W.B. de Groot, G. A.P. Hospers, E. Kapiteijn, D. Piersma, R. S. van Rijn, K. P.M. Suijkerbuijk, A. A.M. van der Veldt, H. M. Westgeest, M. W.J.M. Wouters, J. B.A.G. Haanen & C. A. Uyl-de Groot (2021) - Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs - ESMO Open, 6 (6) - doi: 10.1016/j.esmoop.2021.100320 - [link]
Brenda Leeneman (2021) - Evidence-based decision making on drug reimbursement in melanoma: Using real-world evidence to complement evidence from randomized controlled trials
Brenda Leeneman, Kay Schreuder, Carin A. Uyl - de Groot, Alexander C.J. van Akkooi, John B.A.G. Haanen, Marlies Wakkee, Margreet G. Franken & Marieke W.J. Louwman (2021) - Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study - European Journal of Cancer, 2021 (154), 111-119 - doi: 10.1016/j.ejca.2021.06.007 - [link]
Brenda Leeneman, Hedwig M. Blommestein, Veerle M.H. Coupé, Mathijs P. Hendriks, Wim H.J. Kruit, Peter W. Plaisier, Serge Van Ruth, Albert J. Ten Tije, Michel W.J.M. Wouters, Margreet G. Franken & Carin A. Uyl-De Groot (2021) - Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands - Melanoma Research, 31 (3), 249-257 - doi: 10.1097/cmr.0000000000000732 - [link]